

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA LIEN INTERNATIONAL (HOLDING) COMPANY LIMITED**

**華聯國際（控股）有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 969)**

**CLARIFICATION ANNOUNCEMENT REGARDING INTERIM RESULTS  
ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30th JUNE 2016**

Reference is made to the announcement of Hua Lien International (Holding) Company Limited (the “Company”) in relation to the unaudited condensed consolidated results of the Company and its subsidiaries (the “Group”) for the six months ended 30th June 2016 published on 31st August 2016 (the “Interim Results Announcement”). Capitalised terms used herein shall have the same meaning as those defined in the Interim Results Announcement.

The board of directors of the Company would like to clarify that the change in fair value of derivative component of convertible notes shall be reclassified from administrative expenses and to be separately disclosed for consistency with the presentation of the audited annual reports. Consequential changes are made to the condensed consolidated statement of profit or loss and other comprehensive income for the six months ended 30th June 2016 as disclosed in the Interim Results Announcement on page 1, which should be as follows (the amended parts are bold and underlined for easy reference):

*\* For identification purposes only*

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

*For the six months ended 30th June 2016*

	<i>Notes</i>	<b>Six months ended 30th June</b>	
		<b>2016</b>	2015
		<b>(unaudited)</b>	(unaudited)
		<b>HK\$'000</b>	HK\$'000
Turnover	(3)	<b>148,900</b>	198,154
Cost of sales		<b>(128,734)</b>	(180,358)
Gross profit		<b>20,166</b>	17,796
Changes in fair value of biological assets	(11)	<b>(27,266)</b>	(34,471)
Other income		<b>3,737</b>	3,628
<b><u>Administrative expenses</u></b>		<b><u>(40,006)</u></b>	(42,588)
<b><u>Change in fair value of derivative component of convertible notes</u></b>		<b><u>(1,351)</u></b>	—
Other operating expenses	(4)	<b>(25,698)</b>	(62,575)
Finance costs	(5)	<b>(46,789)</b>	(20,600)
Loss before income tax expense		<b>(117,207)</b>	(138,810)
Income tax expense	(7)	<b>—</b>	—
Loss for the period	(6)	<b>(117,207)</b>	(138,810)

The above clarification does not affect other information contained in the Interim Results Announcement.

By order of the Board  
**Mr. Han Hong**  
*Executive Director*

Hong Kong, 1st September 2016

*As at the date of this announcement, the Board comprises eight directors, of which five are executive directors, namely Mr. Liu Xueyi, Mr. Han Hong, Mr. Hu Yebi, Mr. Wang Zhaohui and Dr. Xu Dandan and three are independent non-executive directors, namely Dr. Zheng Liu, Mr. Yu Chi Jui and Ms. Li Xiao Wei.*